Trials / Completed
CompletedNCT03310190
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
Post-Marketing Observational Study (PMOS) to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 93 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess the real-life management and use of healthcare resources during the initiation of: * Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. * Venetoclax in participants with CLL with the deletion of the short arm of chromosome 17 (del\[17p\]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.
Conditions
Timeline
- Start date
- 2018-01-10
- Primary completion
- 2022-04-30
- Completion
- 2022-04-30
- First posted
- 2017-10-16
- Last updated
- 2023-03-30
Locations
13 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03310190. Inclusion in this directory is not an endorsement.